Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing/treating a thromboembolic disorder, preventing/reducing formation of thrombi, and reducing/inhibiting procoagulant platelet formation. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431). The compositions and kits comprise a cyclosporine analogue.

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating proliferative diseases such as cancer. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (e.g., CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.